本季度信息
根据公告，泰德医药（浙江）股份有限公司2025年度营收预期从2024年的约人民币4.422亿元增长至约人民币5.55亿元至5.85亿元，同比增幅约25.5%至32.3%。公司同时预计2025年度经调整净利润将从2024年的约人民币1.72亿元增长至约人民币2.00亿元至2.30亿元，同比增幅约16.3%至33.7%。
公告显示，此次收入增长主要受集成化CRDMO平台优势及“跟随分子”战略成果推动，同时关键客户对公司服务的需求保持强劲增长，尤其在肽类市场（包括GLP-1领域）上带动了订单规模。经调整净利润的提升在收入增长之外，也得益于公司通过优化运营管理体系获得的成本节约与效率提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.